Every year, more patients skip or ration their medications, not because the treatments fail, but because the price tag acts as a barrier to basic health. The high cost of prescription drugs has become one of the most preventable public health crises in the United States, yet we fail to address the issue. Medicine costs are both a health and justice crisis. 

Drug costs are rising for several reasons. Brand-name drug companies release high-priced specialty drugs for cancer, autoimmune disorders, and rare diseases, with prices increasing annually. According to the Association for Accessible Medicines, the average annual cost of these drugs has tripled in the past decade, from about $18,000 to more than $52,000. Price hikes persist because patent protections block competitors from entering the market, isolating companies as the only marketers. 

The effects of price spikes spread far beyond individual patients. In 2024, Medicaid’s gross spending on prescription drugs topped $100 billion. That is money diverted away from critical services such as preventive care, mental health treatment, and support for rural clinics, all of which keep people healthier in the first place. When drug prices inflate, the entire system pays. Yet, in the pursuit of profit, pharmaceutical companies continue to pump prices.

If we fail to act, we risk permanent damage to public trust, financial stability, and basic health outcomes. Patients will continue rationing insulin and heart medications. Medicaid will strain under unsustainable costs. Those already vulnerable will suffer most because the medicine they rely on will remain overpriced.

Lowering drug prices is not just possible; it is a moral and economic necessity. Although the healthcare system has drifted far from its purpose of caring for the patients it serves, change can still happen. Lawmakers, federal agencies, and state Medicaid programs must curb patent abuse, expand negotiating power, and adopt new models if we want a system that prioritizes patients. We can continue allowing life-saving medicines to function as luxury goods, or we can build a healthcare system where cost never determines who gets to live a healthy life. The path forward is clear, but what remains is the will to take it.